- Home
- NRXP vs ATNM Comparison
NRXP vs ATNM Comparison
Compare NRXP & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- ATNM
- Stock Information
- Founded
- NRXP 2015
- ATNM 2000
- Country
- NRXP United States
- ATNM United States
- Employees
- NRXP N/A
- ATNM N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- ATNM Health Care
- Exchange
- NRXP Nasdaq
- ATNM Nasdaq
- Market Cap
- NRXP 58.5M
- ATNM 50.2M
- IPO Year
- NRXP N/A
- ATNM N/A
- Fundamental
- Price
- NRXP $3.58
- ATNM N/A
- Analyst Decision
- NRXP Strong Buy
- ATNM Strong Buy
- Analyst Count
- NRXP 5
- ATNM 2
- Target Price
- NRXP $31.40
- ATNM $4.50
- AVG Volume (30 Days)
- NRXP 416.8K
- ATNM 108.6K
- Earning Date
- NRXP 11-13-2025
- ATNM 11-13-2025
- Dividend Yield
- NRXP N/A
- ATNM N/A
- EPS Growth
- NRXP N/A
- ATNM N/A
- EPS
- NRXP N/A
- ATNM N/A
- Revenue
- NRXP N/A
- ATNM N/A
- Revenue This Year
- NRXP N/A
- ATNM N/A
- Revenue Next Year
- NRXP $395.09
- ATNM N/A
- P/E Ratio
- NRXP N/A
- ATNM N/A
- Revenue Growth
- NRXP N/A
- ATNM N/A
- 52 Week Low
- NRXP $1.10
- ATNM $1.03
- 52 Week High
- NRXP $6.01
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- NRXP 67.97
- ATNM 45.01
- Support Level
- NRXP $3.19
- ATNM $1.56
- Resistance Level
- NRXP $3.84
- ATNM $1.64
- Average True Range (ATR)
- NRXP 0.22
- ATNM 0.06
- MACD
- NRXP 0.05
- ATNM -0.00
- Stochastic Oscillator
- NRXP 70.87
- ATNM 23.08
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.